Healing & Recovery

BPC-157

Body Protection Compound 157 · pentadecapeptide

well-tolerated mainstream subQ injection / oral capsule

What it is

BPC-157 is a chain of 15 amino acids originally isolated from a stomach-juice protein in 1991. The body produces it naturally as part of the gastric defense system. The synthetic version is one of the most widely used "research peptides" globally and gets nicknamed the "Wolverine peptide" because of how broadly it accelerates tissue healing.

How it works

Think of BPC-157 as a signal that tells damaged tissue to start rebuilding faster than it normally would. It does three main things:

Builds new blood vessels (angiogenesis) into injured areas, getting nutrients and immune cells to the damage site faster.
Activates fibroblasts — the cells that lay down collagen for tendons, ligaments, gut lining, and skin.
Modulates the gut-brain axis via dopamine, serotonin, and nitric oxide pathways — which is why it also tends to reduce systemic inflammation, not just local injury.

Animal studies show it upregulates the growth hormone receptor on tendon cells, making them more responsive to the body's own healing signals.

Benefits

Tendon and ligament healing (Achilles, rotator cuff, knees)
Gut lining repair — widely used for IBS, IBD, leaky gut, and NSAID-induced damage
Soft tissue and muscle recovery from training
Reduces systemic inflammation
Joint pain reduction
Wound healing acceleration
Some neuroprotective and mood-stabilizing effects (dopamine modulation)

Timeline

Week 1: Often-reported reduction in joint pain and gut symptoms within 3–7 days.
Week 2–3: Noticeable improvement in tendon/ligament function and reduced inflammation.
Week 4–6: Major structural healing — this is the typical sweet spot for visible recovery from chronic injuries.
Week 6–8: End of a typical cycle. Most users cycle off here to assess durability of results.

Dosing & titration

Starting dose250–500 mcg, once daily

Standard range250–500 mcg, 1–2x daily

Aggressive (acute)Up to 500 mcg, 2x daily for the first week of an acute injury

Cycle length4–8 weeks on, then 2–4 weeks off

RouteSubQ injection near injury site (gut issues: oral capsule preferred)

When to titrate upIf no symptom change after 2 weeks, increase from 250 to 500 mcg/day. Going beyond 500 mcg twice daily rarely produces additional benefit.

Side effects & risks

BPC-157 has one of the cleanest side-effect profiles in the peptide space — no serious adverse events have been documented in human use to date, and it's exceptionally well tolerated in animal studies. Reported issues are minor:

Local injection site reactions (redness, mild bruising)
Mild lightheadedness or fatigue in the first few doses for some users
Transient nausea with oral form

Theoretical concerns: Because BPC-157 is angiogenic (promotes new blood vessels), it's generally avoided by anyone with active cancer, since tumors also need new blood vessels to grow. The same caution applies to anyone with retinopathy. Banned in WADA-tested professional sports.

Typical price

$60–$120/mo 5 mg vial from a 503A compounding pharmacy — typically lasts 1–2 months at standard doses.

Studies

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025) — Reviews 36 studies across preclinical and clinical use. PubMed Journal of Cartilage & Joint Preservation, 2025
The promoting effect of pentadecapeptide BPC 157 on tendon healing — Foundational study showing accelerated tendon outgrowth, cell survival, and migration. PubMed Journal of Applied Physiology, 2010
Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts — Mechanistic explanation for tendon-healing effect. PubMed Central Molecules, 2018
Achilles detachment in rat and stable gastric pentadecapeptide BPC 157 — Animal model showing accelerated tendon-to-bone healing and protection against corticosteroid-related damage. PubMed Journal of Orthopaedic Research, 2006
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (2025) — Critical balance of benefits and theoretical cancer-risk concerns. PubMed Central Cureus, 2025

Educational reference only. Not medical advice. BPC-157 is not FDA-approved as a drug. Any use should be under guidance of a licensed prescriber.